

# Long-term merger synergies to outweigh near-term merger drag

BFSI - Banks > Analyst Meet Update > September 19, 2023

TARGET PRICE (Rs): 2,100

HDFCB hosted an analyst meet to primarily discuss the adjustments to op. net worth (NW) of eHDFCL and its potential impact on merged NIMs/asset quality aligning with HDFCB's policy framework. As per management, net adjustments to eHDFCL's op. NW of Rs1,340bn as on March 31 would work out to Rs364bn/Rs48 per share and, thus, net adj. NW would be Rs976bn. The adjustments include I-Gaap alignment of Rs118bn, credit harmonization of Rs76bn, DTL impact of Rs49bn, tax shield of Rs40bn, Q1FY24 profit of Rs62bn, dividend payout of Rs81bn, and cancellation of inv/share-swap of Rs142bn. We had largely factored in these adjustments, but for DTL and prudent contingent provisions, which we believe will protect future profitability and boost RoEs. Separately, the bank has quided for calibrated growth in the near term with a focus on building granular liability to replace HDFCL's highcost borrowing and ramping-up the mortgage business from the bank's platform, which coupled with reducing the regulatory drag should lead to margin/RoA normalization. Factoring in incremental NW adjustments, we have lowered our BVPS estimates by 1-2% but expect the bank's RoA/RoE to improve from 1.9%/15.8% in FY24E (merged) to ~2%/17.3% by FY26E, as merger synergies kick in. We retain BUY with a TP of Rs2,100, valuing the core bank at 2.8x Sep-25E ABV and subs/inv. at Rs185/share.

HDFC Bank: Financial Snapshot (Standalone) - Merged financials from FY24E							
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E		
Net profit	369,614	441,101	668,655	774,870	916,466		
Loan growth (%)	20.8	16.9	13.8	15.6	16.6		
NII growth (%)	11.0	20.6	12.6	15.7	18.4		
NIM (%)	3.9	4.1	3.7	3.7	3.8		
PPOP growth (%)	11.7	9.9	13.3	16.4	18.3		
Adj. EPS (Rs)	66.8	79.3	87.9	102.5	121.2		
Adj. EPS growth (%)	18.1	18.6	11.2	16.6	18.3		
Adj. BV (INR)	428.3	497.8	558.9	640.5	734.6		
Adj. BVPS growth (%)	17.5	16.2	4.6	14.6	14.7		
RoA (%)	1.9	1.9	1.9	2.0	2.0		
RoE (%)	16.7	17.0	15.8	16.8	17.3		
P/E (x)	23.3	19.7	16.4	14.1	11.9		
P/ABV (x)	3.6	3.1	2.5	2.2	1.9		

Source: Emkay Research; Merged financials from FY24E

Net worth adjustments stand at 27% of op. NW of eHDFCL as on March 31, 2023: As per management, net adjustments to eHDFCL's op. NW of Rs1,340bn, as on March 31, would work out to Rs364bn/Rs48 per share, including I-Gaap alignment of Rs118bn, credit harmonization of Rs76bn (incl. contingent provisions of Rs39bn), DTL Reserve impact of Rs49bn, tax shield (positive) of Rs40bn, Q1FY24 profit of Rs62bn, interim dividend payout of Rs81bn, and cancellation of investments/share-swap of Rs142bn. Post the adjustment, eHDFCL's NW stands at Rs976bn. As per management, the DTL reserve has been mainly created on lower tax incidence on mortgage portfolio enjoyed by eHDFCL by creating special reserve under Sec. 36, while contingent provisions have been created after factoring in the conservative risk assessment based on the bank's policy. Overall, contingent provisions, including floating provisions, would now be ~Rs150bn/0.7% on merged loan book. Additionally, we believe the bank would recognize consideration from warrant conversion in Q2, while CREDILA's stake sale gains could possibly be recognized in Q3, subject to regulatory approvals.

Excess liquidity and regulatory drag including ICRR impact to hurt margins in Q2, before gradually recovering by Q4: The bank has reported that proforma merged HDFCB's Q1FY24 margins based on interest-earning assets/overall assets stood at 3.9-4%/3.7-3.8% vs. 4.3%/4.1% for the standalone bank. Additionally, the bank has reported that eHDFCL's margin for Q1FY24 stood at 2.7%, which adjusted for terminal excess liquidity and regulatory drag (ex ICRR) stood at 2% postthe merger on 'Day 0'. The bank believes the cumulative effect of ICRR + Excess liquidity + cost catch-up could be 20-25bps in the near term, but margins should gradually recover, led by reduction of ICRR/regulatory drag plus growth acceleration and replacement of eHDFCL's high-cost borrowings. On the liability front, the bank has been ramping up branches and would look at the gradual replacement of HDFCL's high-cost borrowings (80-85% to be replaced via retail deposits) as they mature. The bank also remains open to explore bulk deposits (subject to the right pricing) and would look to build a long-term bond book to match the long-term mortgage book.

#### **Retain BUY**

Factoring in incremental NW adjustments, we have lowered our BVPS estimates for FY24-26E by 1-2%. However, we expect the bank's RoA/RoE to improve from 1.9%/15.8% in FY24E (merged) to ~2%/17.3% by FY26E, benefiting from better growth/margins and fees, as merger synergies kick in. We retain BUY with a TP of Rs2,100 (valuing the core bank at 2.8x its Sep-25E ABV + subs/inv. value at Rs185/share). Further, given KMB undergoing mgmt. transition (typically leading to business/valuation softness as seen in HDFCB), HDFCB with a stable mgmt., better return profile and valuation (2x FY26E ABV vs. 2.1x for KMB) offers a good bet from a medium-long term view. The long-awaited listing of HDB Fin should be another stock catalyst going ahead.

Target Price – 12M	Jun-24
Change in TP (%)	NA
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	28.9
CMP (18-Sep-23) (Rs)	1,629.1

Stock Data	Ticker
52-week High (Rs)	1,758
52-week Low (Rs)	1,365
Shares outstanding (mn)	7,575.6
Market-cap (Rs bn)	12,341
Market-cap (USD mn)	148,207
Net-debt, FY24E (Rs mn)	NA
ADTV-3M (mn shares)	21
ADTV-3M (Rs mn)	34,410.2
ADTV-3M (USD mn)	413.2
Free float (%)	99.0
Nifty-50	20,133
INR/USD	83.3
Shareholding, Jul-23	
Promoters (%)	-
FPIs/MFs (%)	46.6/25.9

Price Performance									
(%) 1M 3M 12M									
Absolute	2.4	1.6	9.1						
Rel. to Nifty (1.8) (5.0) (5.0)									

## 1-Year share price trend (Rs)




Anand Dama anand.dama@emkayglobal.com +91 22 6624 2480

# Dixit Sankharva

dixit.sankharva@emkayglobal.com +91 22 6612 1281

# **Story in Charts**

Exhibit 1: Net adjustments/impact on op. NW of HDFCL works out to Rs364bn/27% of op NW



Source: Company, Emkay Research

Exhibit 2: GNPA ratio for the merged bank is higher because of increased stress recognition in HDFCL's non-individual loan portfolio

Particulars	Mar-23 HDFCB	Jun-23 HDFCB	July 1, 2023 HDFCB Merged
Gross NPA (%)	1.1%	1.2%	1.4%
- Retail GNPA (%)	1.0%	0.9%	0.9%
- CRB GNPA (%)	1.6%	1.8%	1.8%
- CRB ex-Agri GNPA (%)	1.1%	1.2%	1.2%
- Wholesale GNPA (%)	0.5%	0.4%	0.4%
- e-HDFCL Individual GNPA (%)			1.0%
- e-HDFCL Non-Individual GNPA (%)			6.7%
Net NPA (%)	0.3%	0.3%	0.4%
Specific provision coverage (%)	76%	75%	74%
Contingent and floating provisions as a % of advances	0.7%	0.7%	0.7%
Total provisions as a % of advances	2.0%	2.0%	2.2%
Total provisions (ex-specific) as a % of advances	1.1%	1.1%	1.1%


Source: Company, Emkay Research

Exhibit 3: Key Ratios - HDFCB's Standalone vs. Proforma Merged

	HDFCB - S	tandalone	Proforma Merged
Financials	FY23	Q1FY24	Q1FY24
NIM (Interest-bearing assets)	4.3%	4.3%	3.9% - 4.0%
NIM (total assets)	4.1%	4.1%	3.7% - 3.8%
Cost to income	40%	43%	~40%
Credit costs as a % of advances	0.70%	0.70%	~0.6%
RoA	2.1%	2.1%	1.9% - 2.0%
RoE	17.4%	17.3%	~16%
EPS - Standalone	79	21	20
EPS - Consolidated	83	22	22
BVPS - Standalone	502	525	519
BVPS - Consolidated	519	543	536
CAR	19.3%	18.9%	19.2%


Source: Company, Emkay Research

Exhibit 4: FY24 will be a year of consolidation, post which we expect growth to improve as the bank revives from the merger drag and scales up mortgage growth



Source: Emkay Research

Exhibit 5: We expect some softness in NIMs over FY24-25E, mainly due to the recent ICRR impact, regulatory drag and gradual reduction in yields due to a higher share of the floating book (incl. mortgage) but recover gradually as the bank refinances high-cost borrowings with deposits



Source: Emkay Research

Exhibit 6: RoAs (M) to moderate due to margin pressure/higher opex, but to gradually recover as merger synergies kick in






Exhibit 7: ...which along with better growth/leverage should help it




Source: Emkay Research; M - Merged, S - Standalone bank pre-merger




Source: Emkay Research; M - Merged, S - Standalone bank pre-merger

## Exhibit 8: HDFCB to report healthy RoE by FY26E (better than KMB)




Source: Emkay Research; \*Partly inflated due to lower capital \*\*Partly suppressed due to higher capital

#### Exhibit 9: ...but still trades at a slight discount to KMB



Source: Emkay Research; P/ABV adj. for subs. valuations

Exhibit 10: HDFCB trades at a valuation of 2.4x its one-year forward ABV



Source: Bloomberg, Emkay Research

Exhibit 11: Revision in estimates for the merged bank

Y/E March (Rs mn)	FY24E		FY25E		FY26E				
	Earlier	Revised	Change (%)	Earlier	Revised	Change (%)	Earlier	Revised	Change (%)
Net income	1,670,432	1,680,924	0.6%	1,970,699	1,975,990	0.3%	2,333,271	2,332,834	0.0%
PPOP	1,040,312	1,044,390	0.4%	1,211,554	1,215,551	0.3%	1,439,452	1,437,486	-0.1%
PAT	665,716	668,655	0.4%	774,071	774,870	0.1%	917,938	916,466	-0.2%
EPS (Rs)	87.5	87.9	0.4%	102.4	102.5	0.1%	121.4	121.2	-0.2%
BV (Rs)	577.5	567.9	-1.7%	661.3	651.8	-1.4%	757.6	747.9	-1.3%

Source: Emkay Research

**Exhibit 12: Key Assumptions** 

	FY23A	FY24E	FY25E	FY26E
Loan Growth (%)	14.8	13.8	15.6	16.6
Deposit Growth (%)	18.3	19.7	20.2	22.0
NIM (%)	3.8	3.7	3.7	3.8
GNPA (%)	1.2	1.3	1.4	1.4
Credit Cost (%)	0.7	0.7	0.7	0.7

Source: Emkay Research

# HDFC Bank: Standalone Financials and Valuations (Merged financials from FY24E)

Profit and Loss					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Interest Income	1,277,531	1,615,856	2,742,321	3,029,330	3,412,569
Interest Expense	557,435	747,433	1,547,257	1,646,384	1,775,785
Net interest income	720,096	868,422	1,195,065	1,382,946	1,636,784
NII growth (%)	11.0	20.6	12.6	15.7	18.4
Other income	295,099	312,162	485,860	593,045	696,050
Total Income	1,015,195	1,180,585	1,680,924	1,975,990	2,332,834
Operating expenses	374,422	476,521	636,534	760,440	895,348
PPOP	640,773	704,064	1,044,390	1,215,551	1,437,486
PPOP growth (%)	11.7	9.9	13.3	16.4	18.3
Core PPOP	617,947	717,475	952,955	1,097,643	1,307,787
Provisions & contingencies	150,618	119,197	150,466	179,629	212,263
PBT	490,155	584,867	893,924	1,035,922	1,225,222
Extraordinary items	0	0	0	0	0
Tax expense	120,541	143,766	225,269	261,052	308,756
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	369,614	441,101	668,655	774,870	916,466
PAT growth (%)	18.8	19.3	10.8	15.9	18.3
Adjusted PAT	369,614	441,101	668,655	774,870	916,466
Diluted EPS (Rs)	66.3	78.7	119.7	139.8	165.4
Diluted EPS growth (%)	17.8	18.6	11.3	16.8	18.3
DPS (Rs)	15.5	19.1	20.9	22.0	25.0
Dividend payout (%)	23.3	24.0	23.8	21.5	20.6
Effective tax rate (%)	24.6	24.6	25.2	25.2	25.2
Net interest margins (%)	3.9	4.1	3.7	3.7	3.8
Cost-income ratio (%)	36.9	40.4	37.9	38.5	38.4
Shares outstanding (mn)	5,545.5	5,579.7	7,562.4	7,562.4	7,562.4

Source: Company, Emkay Research	; Merged financials from FY24E
---------------------------------	--------------------------------

Asset Quality and Ot	her Metric	s			
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Asset quality					
Gross NPLs	161,409.3	180,190.0	340,557.5	404,400.3	481,408.0
Net NPLs	44,076.7	43,684.2	91,950.5	113,232.1	134,794.2
GNPA ratio (%)	1.2	1.1	1.3	1.4	1.4
NNPA ratio (%)	0.3	0.3	0.4	0.4	0.4
Provision coverage (%)	72.7	75.8	73.0	72.0	72.0
Gross slippages	268,614.3	244,000.0	393,574.1	425,618.7	513,384.2
Gross slippage ratio (%)	1.9	1.5	1.6	1.5	1.5
LLP ratio (%)	1.2	0.8	0.7	0.7	0.7
NNPA to net worth (%)	1.8	1.5	2.1	2.2	2.3
Capital adequacy					
Total CAR (%)	18.9	19.3	18.3	18.1	17.9
Tier-1 (%)	17.9	17.1	16.6	16.6	16.6
CET-1 (%)	16.7	16.4	15.5	15.7	15.8
RWA-to-Total Assets (%)	65.4	64.3	66.0	66.0	66.0
Miscellaneous					
Total income growth (%)	7.7	22.6	27.6	12.2	13.4
Opex growth (%)	14.4	27.3	27.1	19.5	17.7
Core PPOP growth (%)	15.5	16.1	2.7	15.2	19.1
PPOP margin (%)	40.7	36.5	32.4	33.6	35.0
PAT/PPOP (%)	57.7	62.7	64.0	63.7	63.8
LLP-to-Core PPOP (%)	24.4	16.6	15.8	16.4	16.2
Yield on advances (%)	7.9	8.6	9.5	9.1	8.9
Cost of funds (%)	3.5	3.9	5.4	4.9	4.6

Source: Company, Emkay Research; Merged financials from FY24E

Balance Sheet					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	5,546	5,580	7,562	7,562	7,562
Reserves & surplus	2,395,384	2,796,424	4,312,734	4,921,231	5,648,639
Net worth	2,400,929	2,802,004	4,320,296	4,928,794	5,656,201
Deposits	15,592,174	18,833,947	24,357,036	29,268,153	35,693,947
Borrowings	1,848,172	2,067,656	6,432,836	6,737,977	6,225,339
Interest-bearing liab.	17,440,346	20.901.602	30,789,872	36.006.131	41.919.287
Other liabilities & prov.	844,075	957,209	1,701,684	1,407,745	1,466,558
Total liabilities & equity	20,685,351	24,660,815	36,811,851	42,342,669	49,042,046
Net advances	13,688,209	16,005,859	25,143,272	29,061,844	33,878,998
Investments	4,555,357	5,170,014	7,067,327	8,184,243	9,414,928
Cash, other balances	1,523,269	1,937,651	2,463,190	2,736,466	3,143,946
Interest earning assets	19.766.835	23.113.524	34,673,788	39.982.553	46.437.873
Fixed assets	60,837	80,165	121,443	130,465	140,350
Other assets	857,678	1,467,125	2,016,620	2,229,652	2,463,823
Total assets	20,685,351	24 660 815	36 811 851	42 342 660	49 042 046
BVPS (Rs)	434.2	503.7	567.9	651.8	747.9
Adj. BVPS (INR)	428.3	497.8	558.9	640.5	734.6
Gross advances	13,805,542	16,142,365	25,391,879	29,353,012	34,225,612
Credit to deposit (%)	87.8	85.0	103.2	99.3	94.9
CASA ratio (%)	48.2	44.4	38.4	36.5	35.4
Cost of deposits (%)	3.4	3.7	4.8	4.6	4.4
Loans-to-Assets (%)	66.2	64.9	68.3	68.6	69.1
Net advances growth (%)	20.8	16.9	13.8	15.6	16.6
Deposit growth (%)	16.8	20.8	19.7	20.2	22.0
Book value growth (%)	17.2	16.0	4.7	14.8	14.8

Source: Company, Emkay Research; Merged financials from FY24E

Valuations and Key Ratios								
Y/E March	FY22	FY23	FY24E	FY25E	FY26E			
P/E (x)	23.3	19.7	16.4	14.1	11.9			
P/B (x)	3.6	3.1	2.5	2.2	1.9			
P/ABV (x)	3.6	3.1	2.6	2.3	2.0			
P/PPOP (x)	13.6	12.4	10.6	9.1	7.7			
Dividend yield (%)	1.0	1.2	1.3	1.4	1.5			
DuPont-RoE split (%)								
NII/avg assets	3.8	3.8	3.5	3.5	3.6			
Other income	1.5	1.4	1.4	1.5	1.5			
Fee income	1.0	1.1	1.1	0.8	0.9			
Opex	2.0	2.1	1.9	1.9	2.0			
PPOP	3.4	3.1	3.0	3.1	3.1			
Core PPOP	3.2	3.2	2.8	2.8	2.9			
Provisions	0.8	0.5	0.4	0.5	0.5			
Tax expense	0.6	0.6	0.7	0.7	0.7			
RoA (%)	1.9	1.9	1.9	2.0	2.0			
Leverage ratio (x)	8.6	8.7	8.1	8.6	8.6			
RoE (%)	16.7	17.0	15.8	16.8	17.3			
Quarterly data								
Rs mn, Y/E March	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24			
NII	194,814	210,212	229,878	233,518	235,991			
NIM (%)	4.2	4.3	4.3	4.3	4.3			
PPOP	153,678	173,922	190,241	186,209	187,720			
PAT	91,960	106,058	122,595	120,475	119,518			
EPS (Rs)	16.56	19.04	21.98	21.59	21.37			


Source: Company, Emkay Research; Merged financials from FY24E

# **RECOMMENDATION HISTORY - DETAILS**

Date	CMP (INR)	TP (INR)	Rating	Analyst
11-Sep-23	1,632	2,100	Buy	Anand Dama
17-Jul-23	1,679	2,150	Buy	Anand Dama
25-May-23	1,610	2,050	Buy	Anand Dama
24-Apr-23	1,688	2,050	Buy	Anand Dama
15-Apr-23	1,692	2,050	Buy	Anand Dama
09-Mar-23	1,631	1,925	Buy	Anand Dama
15-Jan-23	1,601	1,925	Buy	Anand Dama
04-Jan-23	1,610	1,800	Buy	Anand Dama
16-Oct-22	1,439	1,800	Buy	Anand Dama
04-Oct-22	1,453	1,800	Buy	Anand Dama
17-Jul-22	1,362	1,800	Buy	Anand Dama
01-Jun-22	1,395	1,800	Buy	Anand Dama
23-May-22	1,304	1,800	Buy	Anand Dama
18-Apr-22	1,395	1,950	Buy	Anand Dama
05-Apr-22	1,608	2,050	Buy	Anand Dama
04-Apr-22	1,657	2,050	Buy	Anand Dama
16-Jan-22	1,545	2,050	Buy	Anand Dama
04-Jan-22	1,529	2,050	Buy	Anand Dama
17-Oct-21	1,687	2,050	Buy	Anand Dama
05-Oct-21	1,595	1,850	Buy	Anand Dama
18-Jul-21	1,522	1,850	Buy	Anand Dama
18-Apr-21	1,429	1,850	Buy	Anand Dama
05-Apr-21	1,450	1,850	Buy	Anand Dama
20-Jan-21	1,492	1,850	Buy	Anand Dama
17-Jan-21	1,467	1,850	Buy	Anand Dama
06-Jan-21	1,421	1,500	Buy	Anand Dama
18-Oct-20	1,199	1,500	Buy	Anand Dama
05-Oct-20	1,114	1,300	Buy	Anand Dama

Source: Company, Emkay Research

## **RECOMMENDATION HISTORY - TREND**



Source: Bloomberg, Company, Emkay Research

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group, Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India, EGFSL was established in 1995 and is one of India's leading brokerage and distribution house, EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkavglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness quaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

#### RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

1 An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of September 19, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report 3. during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of September 19, 2023
  EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject
- 5 company at the end of the month immediately preceding the September 19, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

#### Emkay Pating Distribution

Elikay Rating Distribution			
Ratings	Expected Return within the next 12-18 months.		
BUY	Over 15%		
HOLD	Between -5% to 15%		
SELL	Below -5%		

### Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

#### OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company,

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.